A study collecting samples and scans from people with brain and spine lymphoma
Original title: Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is given, and this study collects samples rather than testing a treatment.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study gathers samples over time to learn how this cancer behaves.
Who this trial is for. This study is for people having a biopsy of a growth in the brain or spine. It collects tissue, spinal fluid, blood, urine, saliva, and stool from people whose tests show lymphoma.
Where it stands. The study has not reported results. It follows people with brain MRI scans and repeat fluid and blood samples. Visits happen 1 month after the biopsy, then every 3 to 6 months. The team wants to see how the samples line up with treatment response and the cancer coming back. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This study is about learning, not about testing a new drug. The goal is to find signs in spinal fluid and blood that show how the cancer is doing. That could help doctors track this cancer better in the future. Someone who fits might ask their care team about it.
What it doesn't mean: This does not mean help is here now. A trial is a test, not a proven treatment. Being in one is not a guarantee of any benefit. It is not a promise of a cure. This study also does not offer a new treatment.
Source: ClinicalTrials.gov, September 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.